EBMT 2024 | Promising novel immunotherapeutic approaches in lymphoma

So other novel immunotherapy approaches which are also, you know, enriching for these patients, which don’t have other treatment options are tafasitamab, lenalidomide. This would be the combination of an antibody targeting CD19 together with an immunomodulatory agent such as lenalidomide. This is approved based on the L-MIND trial. And it’s true that data in the real world setting has not shown such encouraging results as the pivotal trial, but still waiting to see, you know, larger data sets.

We also have antibody-drug conjugates such as loncastuximab tesirine, which at this meeting in fact has shown encouraging real world data and patients who have been previously exposed to CAR T-cell therapy, so that’s another novel option we can offer our patients who are relapsing to CAR-T’s or bispecific antibodies.

And of course, we have polatuzumab, rituximab, bendamustine, another antibody-drug conjugate in this case targeting CD19B, which has, you know, abundant real world data with overall response rate ranging from 50 to 60% and complete response rates ranging from 30 to 40%.

So I think these three combinations are R-Benda-Pola, TAFA-LEN, and loncastuximab would be the novel immunotherapy approaches, which are the up and comers, coming a little bit behind perhaps CAR T-cells and bispecific antibodies, but still encouraging results and exciting data for the future.